QTORIN™ platform is a patented and versatile platform designed to generate new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare skin diseases.
The Power of QTORIN™
Palvella’s proprietary QTORIN™ platform was developed over several years of research to overcome inherent challenges with topical delivery across a wide range of drugs including rapamycin. The challenges of topical delivery include high molecular weight, chemical and physical instability, acceptable drug concentrations and targeting skin penetration to achieve limited systemic absorption. The QTORIN™ platform overcomes these challenges to topical delivery and is compatible with a diverse range of cargoes for targeted delivery to the site of pathology, usually within the deep layers of epidermis or dermis. All of Palvella’s programs, including QTORINTM rapamycin 3.9% and PTX-014, leverage QTORIN™ to deliver the active cargos directly to the site of genetic pathology of each disease. QTORIN™ offers potential applicability to a wide range of diseases and drugs, including single agents and fixed combinations.
QTORINTM confers excellent stability to rapamycin, which is highly susceptible to degradation. Our QTORINTM rapamycin 3.9% is stable at room temperature in our pump dispenser for extended periods.
Enables Therapeutic Concentrations
QTORINTM rapamycin 3.9% topical gel is a high-strength formulation that is providing local and targeted therapeutic effect with minimal systemic absorption.
Targeted Skin Distribution
Prior to QTORIN™ platform, rapamycin had very poor skin absorption due to its high molecular weight and chemical properties. QTORINTM rapamycin 3.9% formulation yields optimal epidermal and dermal distribution with systemic absorption achieving only picogram levels in clinical studies.